CN101426523B - 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗 - Google Patents
基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗 Download PDFInfo
- Publication number
- CN101426523B CN101426523B CN2006800543552A CN200680054355A CN101426523B CN 101426523 B CN101426523 B CN 101426523B CN 2006800543552 A CN2006800543552 A CN 2006800543552A CN 200680054355 A CN200680054355 A CN 200680054355A CN 101426523 B CN101426523 B CN 101426523B
- Authority
- CN
- China
- Prior art keywords
- cell
- antigen
- galcer
- vaccine
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 237
- 239000000427 antigen Substances 0.000 title claims abstract description 128
- 108091007433 antigens Proteins 0.000 title claims abstract description 128
- 102000036639 antigens Human genes 0.000 title claims abstract description 128
- 210000000581 natural killer T-cell Anatomy 0.000 title abstract description 49
- 229940030156 cell vaccine Drugs 0.000 title abstract description 43
- 239000003446 ligand Substances 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 229960005486 vaccine Drugs 0.000 claims abstract description 78
- VJLLLMIZEJJZTE-VNQXHBPZSA-N HexCer(d18:1/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O VJLLLMIZEJJZTE-VNQXHBPZSA-N 0.000 claims description 288
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 38
- 238000010361 transduction Methods 0.000 claims description 36
- 230000026683 transduction Effects 0.000 claims description 35
- 241000701161 unidentified adenovirus Species 0.000 claims description 29
- 230000003053 immunization Effects 0.000 claims description 26
- 238000002649 immunization Methods 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 19
- 238000002560 therapeutic procedure Methods 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 10
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 7
- 241000701806 Human papillomavirus Species 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- 241000607768 Shigella Species 0.000 claims description 6
- -1 PT Proteins 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical group CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims description 4
- 241000588832 Bordetella pertussis Species 0.000 claims description 4
- 241000222122 Candida albicans Species 0.000 claims description 4
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000590002 Helicobacter pylori Species 0.000 claims description 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 229940095731 candida albicans Drugs 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229940037467 helicobacter pylori Drugs 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 208000003265 stomatitis Diseases 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 3
- 206010013023 diphtheria Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 241000589972 Borrelia sp. Species 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims description 2
- 108010049048 Cholera Toxin Proteins 0.000 claims description 2
- 102000009016 Cholera Toxin Human genes 0.000 claims description 2
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 2
- 101710154643 Filamentous hemagglutinin Proteins 0.000 claims description 2
- 101710154606 Hemagglutinin Proteins 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 208000005331 Hepatitis D Diseases 0.000 claims description 2
- 206010019773 Hepatitis G Diseases 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 108010008707 Mucin-1 Proteins 0.000 claims description 2
- 108010006232 Neuraminidase Proteins 0.000 claims description 2
- 102000005348 Neuraminidase Human genes 0.000 claims description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 2
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 2
- 101710176177 Protein A56 Proteins 0.000 claims description 2
- 241000710960 Sindbis virus Species 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 231100000655 enterotoxin Toxicity 0.000 claims description 2
- 239000000185 hemagglutinin Substances 0.000 claims description 2
- 208000005252 hepatitis A Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 238000012737 microarray-based gene expression Methods 0.000 claims description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
- 108010021711 pertactin Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims 2
- 244000052616 bacterial pathogen Species 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241001040659 Plasmodium (Plasmodium) Species 0.000 claims 1
- 101710167605 Spike glycoprotein Proteins 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 abstract description 86
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 33
- 230000000259 anti-tumor effect Effects 0.000 abstract description 23
- 230000004044 response Effects 0.000 abstract description 22
- 230000001404 mediated effect Effects 0.000 abstract description 15
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 7
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 4
- 229930186217 Glycolipid Natural products 0.000 abstract description 4
- 229940029030 dendritic cell vaccine Drugs 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940021993 prophylactic vaccine Drugs 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 128
- 210000004027 cell Anatomy 0.000 description 113
- 210000001744 T-lymphocyte Anatomy 0.000 description 37
- 238000011081 inoculation Methods 0.000 description 36
- 230000036039 immunity Effects 0.000 description 34
- 230000001939 inductive effect Effects 0.000 description 28
- 238000000034 method Methods 0.000 description 27
- 230000004913 activation Effects 0.000 description 24
- 102100037850 Interferon gamma Human genes 0.000 description 23
- 108010074328 Interferon-gamma Proteins 0.000 description 23
- 230000003013 cytotoxicity Effects 0.000 description 23
- 231100000135 cytotoxicity Toxicity 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 238000011740 C57BL/6 mouse Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 18
- 102000000588 Interleukin-2 Human genes 0.000 description 17
- 108010002350 Interleukin-2 Proteins 0.000 description 17
- 210000000612 antigen-presenting cell Anatomy 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 238000012545 processing Methods 0.000 description 16
- 238000010253 intravenous injection Methods 0.000 description 15
- 239000000546 pharmaceutical excipient Substances 0.000 description 15
- 238000002372 labelling Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 210000004988 splenocyte Anatomy 0.000 description 13
- 238000005336 cracking Methods 0.000 description 12
- 238000011725 BALB/c mouse Methods 0.000 description 11
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 210000004691 chief cell of stomach Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 230000005809 anti-tumor immunity Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000003844 B-cell-activation Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 241000699729 Muridae Species 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 229940102223 injectable solution Drugs 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 229940126530 T cell activator Drugs 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
- IRPOZWRRAFKYMQ-LMIAXWKISA-N 1-O-(alpha-D-galactopyranuronosyl)-N-tetradecanoyldihydrosphingosine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](NC(=O)CCCCCCCCCCCCC)CO[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O IRPOZWRRAFKYMQ-LMIAXWKISA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101100291915 Candida albicans (strain SC5314 / ATCC MYA-2876) MP65 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100033299 Glia-derived nexin Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 108700023315 OspC Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 241000736131 Sphingomonas Species 0.000 description 1
- 241001135759 Sphingomonas sp. Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- UCKDWANVYDOPEV-SVYNEFFASA-N alpha-glucuronosylceramide Chemical compound CCCCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCCCC)CO[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O UCKDWANVYDOPEV-SVYNEFFASA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000008350 antigen-specific antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- MKXZASYAUGDDCJ-CGTJXYLNSA-N levomethorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(C)[C@@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-CGTJXYLNSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000008146 mannosides Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940033515 pneumovax 23 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008771 sex reversal Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2006/001589 WO2007126163A1 (en) | 2006-04-27 | 2006-04-27 | B cell-based vaccine loaded with the ligand of natural killer t cell and antigen |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101426523A CN101426523A (zh) | 2009-05-06 |
CN101426523B true CN101426523B (zh) | 2013-03-27 |
Family
ID=38655669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800543552A Active CN101426523B (zh) | 2006-04-27 | 2006-04-27 | 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2029165B1 (de) |
JP (1) | JP4713638B2 (de) |
CN (1) | CN101426523B (de) |
BR (1) | BRPI0621599B1 (de) |
ES (1) | ES2529257T3 (de) |
WO (1) | WO2007126163A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8916164B2 (en) | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
KR100995340B1 (ko) * | 2007-11-19 | 2010-11-19 | 재단법인서울대학교산학협력재단 | 자연 살해 t 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신 |
BRPI0820960B8 (pt) | 2007-12-05 | 2021-05-25 | Abivax | composição, composição farmacêutica, e uso da composição |
KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
CA2739765A1 (en) * | 2008-10-08 | 2010-04-15 | Vincent Serra | Vaccine composition for use against influenza |
EP2198879A1 (de) | 2008-12-11 | 2010-06-23 | Institut Curie | CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle |
EP2683402B1 (de) | 2011-03-11 | 2020-06-24 | Turnstone Limited Partnership | Impfverfahren mit einem histon-deacetylase-hemmer |
CN103463631B (zh) * | 2013-09-02 | 2015-07-01 | 东南大学 | 一种基于Hepa1-6肝癌细胞自噬小体-DRibbles的B细胞疫苗及其制备方法 |
CN107206258A (zh) | 2015-02-10 | 2017-09-26 | 俄亥俄州创新基金会 | 衣原体激活的b细胞平台及其方法 |
CN105087649B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 携带muc-1抗原基因的重组腺相关病毒载体及构建方法与应用 |
EP3373961A4 (de) | 2015-11-10 | 2019-07-31 | Ohio State Innovation Foundation | Verfahren und zusammensetzungen in zusammenhang mit humoraler affinität |
AU2017294751B2 (en) * | 2016-07-13 | 2023-10-05 | Ohio State Innovation Foundation | Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity |
US20220193129A1 (en) * | 2017-04-27 | 2022-06-23 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents and dosages thereof |
CN107488677A (zh) * | 2017-09-14 | 2017-12-19 | 中国疾病预防控制中心病毒病预防控制所 | 一株携带eb病毒潜伏膜抗原2基因的重组痘苗病毒及其应用 |
WO2020237158A1 (en) * | 2019-05-23 | 2020-11-26 | Uti Limited Partnership | Nanoparticles comprising non-classical mhc and uses thereof |
-
2006
- 2006-04-27 CN CN2006800543552A patent/CN101426523B/zh active Active
- 2006-04-27 WO PCT/KR2006/001589 patent/WO2007126163A1/en active Application Filing
- 2006-04-27 BR BRPI0621599-8A patent/BRPI0621599B1/pt active IP Right Grant
- 2006-04-27 JP JP2008513353A patent/JP4713638B2/ja active Active
- 2006-04-27 EP EP06757562.1A patent/EP2029165B1/de active Active
- 2006-04-27 ES ES06757562.1T patent/ES2529257T3/es active Active
Non-Patent Citations (4)
Title |
---|
CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis;F Fais等;《leukemia》;20051231;第19卷;第551页摘要,右栏,第554页表1 * |
F Fais等.CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis.《leukemia》.2005,第19卷第551-556. |
FRANK.HSU等.vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.《nature medicine》.1996,第2卷(第1期),52-58. |
vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells;FRANK.HSU等;《nature medicine》;19961231;第2卷(第1期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
BRPI0621599B1 (pt) | 2021-07-27 |
ES2529257T3 (es) | 2015-02-18 |
BRPI0621599A2 (pt) | 2011-12-13 |
EP2029165A1 (de) | 2009-03-04 |
WO2007126163A1 (en) | 2007-11-08 |
EP2029165B1 (de) | 2014-12-03 |
EP2029165A4 (de) | 2010-08-18 |
CN101426523A (zh) | 2009-05-06 |
BRPI0621599A8 (pt) | 2019-01-22 |
JP2008527051A (ja) | 2008-07-24 |
JP4713638B2 (ja) | 2011-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101426523B (zh) | 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗 | |
CN101861167B (zh) | 包含装载有抗原和自然杀伤t细胞配体的单核细胞或未成熟骨髓细胞(imc)的疫苗 | |
Yoshikawa et al. | Nanoparticles built by self-assembly of amphiphilic γ-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells | |
US7553661B2 (en) | Stromal antigen-presenting cells and use thereof | |
Goldstein et al. | A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors | |
CN102245204A (zh) | α-半乳糖基神经酰胺类似物以及它们作为免疫疗法、佐剂和抗病毒剂、抗细菌剂和抗癌剂的应用 | |
CN101511384A (zh) | 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞 | |
Kjaergaard et al. | Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine | |
CN102076359A (zh) | 疫苗组合物和方法 | |
CN102172397A (zh) | 树突细胞的体内靶向 | |
Dashtsoodol et al. | Natural killer T cell-targeted immunotherapy mediating long-term memory responses and strong antitumor activity | |
Kogo et al. | Suppression of murine tumour growth through CD 8+ cytotoxic T lymphocytes via activated DEC‐205+ dendritic cells by sequential administration of α‐galactosylceramide in vivo | |
KR100809873B1 (ko) | 자연 살해 t 세포의 리간드와 항원을 적재한 b 세포를매개로 하는 백신 | |
Subrahmanyam et al. | Boosting the immune response: the use of i NKT cell ligands as vaccine adjuvants | |
US8003093B2 (en) | B cell-based vaccine loaded with the ligand of natural killer T cell and antigen | |
Shin et al. | Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy | |
KR101055666B1 (ko) | 자연 살해 t 세포의 리간드와 항원을 적재한 단핵구 또는 미분화 골수성 세포를 포함하는 백신 | |
Bianchi et al. | Idiotypic vaccination in B-cell malignancies | |
KR20100072211A (ko) | 보체 활성 향상을 위한 백신 조성물 | |
RU2420311C2 (ru) | Вакцина на основе в-клеток, нагруженных лигандом т-клеток-природных киллеров и антигеном | |
JP2011102320A (ja) | ナチュラルキラーt細胞のリガンドと抗原を積載したb細胞を媒介とするワクチン | |
Kim et al. | Gene transfer of AIMP1 and B7. 1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice | |
KR20240037865A (ko) | 자연 살해 t 세포의 리간드와 항원을 적재한 말초혈액단핵세포를 포함하는 백신 | |
Nitcheu et al. | Preclinical and Clinical Development of Synthetic i NKT-Cell Glycolipid Agonists as Vaccine Adjuvants | |
Garlie et al. | Enrichment of CD14+ Cells for Dendritic Cell Production Using the Elutra™ Cell Separation System |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: XILIDE CORPORATION Free format text: FORMER OWNER: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION Effective date: 20140820 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140820 Address after: Seoul, South Kerean Patentee after: Xilide Co. Ltd. Address before: Seoul, South Kerean Patentee before: Seoul Nat University Industry |